Literature DB >> 9023570

Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy.

M J Hodgman1, T G Martin, E P Krenzelok.   

Abstract

A number of novel serotonergic antidepressants have been introduced to clinical practice over the last decade. These medications are felt to be safe alternatives to the traditional tricyclic antidepressants and monoamine oxidase inhibitors, particularly in the overdose setting. Serious adverse reactions and drug interactions have been appreciated and fatalities have been reported. We describe the development of the serotonin syndrome in a 60 year old female on chronic tranylcypromine treatment following the inadvertent ingestion of a single dose of venlafaxine. Manifestations included and altered mental status that progressed to hyperthermia and coma. She recovered quickly and without complications. Health care providers and poison specialists need to be aware that this potentially serious syndrome can be precipitated by a single dose of a serotonin reuptake inhibitor in patients being treated with a monoamine oxidase inhibitor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9023570     DOI: 10.1177/0960327197016001031

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  3 in total

Review 1.  Venlafaxine extended-release: a review of its use in the management of major depression.

Authors:  K Wellington; C M Perry
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  Venlafaxine in the treatment of panic disorder.

Authors:  Martin A Katzman; Leslie Jacobs
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

3.  Venlafaxine extended release (XR) in the treatment of panic disorder.

Authors:  Kevin Kjernisted; Diane McIntosh
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.